Ultrahuman reports Rs 565 Cr revenue and Rs 73 Cr profit in FY25

After recording over 15X growth in revenue between FY22 and FY24, wearable tech startup Ultrahuman delivered another 5X year-on-year surge during FY25. Alongside this growth, the Bengaluru-based company also turned profitable during the fiscal year ending March 2025.

Ultrahuman’s revenue from operations jumped to Rs 565 crore in FY25 from Rs 105 crore in FY24, according to the company’s consolidated financial statements reviewed by Entrackr.

Ultrahuman operates as a self-quantification platform with products including its flagship smart ring Ring Air, glucose monitoring wearable M1 Live, and blood testing solution Blood Vision. Smart rings emerged as the company’s mainstay, contributing 91.3% of operating revenue, which grew 9.5X to Rs 516 crore in the last fiscal year.

Its subscription income increased 7.4% to Rs 29 crore, while other operating revenue stood at Rs 20 crore. Including other income from interest and gains on mutual funds, the company’s overall income rose 5.4X to Rs 581 crore in FY25, up from Rs 108 crore in FY24.

The company has a holding entity in India and four wholly-owned subsidiaries across the US, UK, and the Middle East. The US remains Ultrahuman’s largest market with a 61.4% share, followed by the UK (4.5%), the Middle East (5.9%), and India (2.7%).

As per a report shared earlier this year, Ultrahuman said its retail sales climbed to 35% in 2024, up from 20% in 2023, while D2C contributed 41%. Growth was driven by strong traction in emerging markets such as Thailand, Hungary, and Germany, along with sustained demand in core geographies including the US, India, UAE, and the UK.

On the cost front, procurement expenses stood at Rs 95 crore, while employee benefits were recorded at Rs 52 crore. Advertising, selling, and distribution together consumed Rs 142 crore in FY25. Job work, website maintenance, legal, spare parts, and other overheads pushed Ultrahuman’s total expenditure to Rs 535 crore during the fiscal year.

A sharp scale-up combined with controlled costs helped Ultrahuman swing into the black, posting its first-ever profit of Rs 73 crore in FY25, compared to a loss of Rs 38 crore in FY24. Its ROCE and EBITDA margin improved to 12.9% and 8.76%, respectively.

At the unit level, the company spent Re 0.95 to earn a rupee in FY25. As of March 2024, its total current assets stood at Rs 544 crore, including Rs 80 crore in cash and bank balances.

The company disclosed in its annual report that on August 22, 2025, Ultrahuman Healthcare Limited, a wholly owned subsidiary, entered into a share purchase agreement to acquire 100% of viO HealthTech Limited, thereby strengthening women’s cycle and ovulation tracking capabilities for its smart rings.

Ultrahuman has raised over $60 million to date, including a $35 million Series B round led by Zomato founder and CEO Deepinder Goyal alongside existing backers. Nexus Ventures holds the largest external stake at 17.26%, followed by Blume Ventures, while co-founders Mohit Kumar and Vatsal Singhal jointly own 28.9% of the company.